View on Pubmed.gov 41627042 | View on doi.org 10.1097/JCN.000...
Preventing Posttraumatic Stress Disorder After an Implantable Cardioverter Defibrillator Shock With a Heart Rate Self-Monitoring Intervention: A Feasibility Study.
- Cynthia M. Dougherty, PhD, ARNP, FAAN, FAHA, Charles and Gerda Endowed Professor in Nursing, University of Washington School of Nursing, and Adjunct Professor, Biobehavioral Nursing and Health Informatics, University of Washington School of Medicine, Seattle.
- Elizabeth Frazier, MSN, RN, Doctoral Student, Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle.
- Wei-Lun Chang, PhD, MSN, RN, Doctoral Student, Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle.
- Elaine A. Thompson, PhD, MA, RN, Professor Emeritus, Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle.
Abstract
BACKGROUND
Implantable cardioverter defibrillator (ICD) shocks are unexpected, painful, traumatic, and can lead to posttraumatic stress disorder (PTSD).
OBJECTIVE
To describe the feasibility and efficacy of the Heart Rate Self-Monitoring (HRSM) intervention to reduce PTSD symptoms post-ICD shock.
METHODS
A single-group, prepost design was used to assess study outcomes. In the HRSM intervention we used Polar HR monitoring and 4-weekly, nurse-led coaching sessions to review responses to tailored walking and deep breathing exercises. Outcomes included ICD shock anxiety, PTSD symptoms, depression, steps/day, self-efficacy, and salivary cortisol.
RESULTS
Ten participants (100% male, 89% Caucasian, 58 years, and 55% prior ICD shock) completed the study. Intervention feasibility was established. Postintervention, ICD shock anxiety (P = .03), PTSD symptoms (P = .06), self-monitoring behaviors (P = .02), and salivary cortisol (P = .10) decreased. Steps/day and depression remained stable.
CONCLUSION
After ICD shock, participation in HRSM was associated with decreased anxiety, PTSD symptoms, and salivary cortisol.
References
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e272–e391. doi:10.1161/cir.0000000000000549.
Saeed M, Hanna I, Robotis D, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE Study. J Cardiovasc Electrophysiol. 2014;25(1):52–59. doi:10.1111/jce.12273.
Pedersen SS, van den Broek KC, van den Berg M, Theuns DAMJ. Shock as a determinant of poor patient-centered outcomes in implantable cardioverter defibrillator patients: is there more to it than meets the eye? Pacing Clin Electrophysiol. 2010;33(12):1430–1436. doi:10.1111/j.1540-8159.2010.02845.x.
Sears SF, Harrell R, Sorrell A., et al. Addressing PTSD in implantable cardioverter defibrillator patients: state-of-the-art management of ICD shock and PTSD. Curr Cardiol Rep. 2023;25(9):1029–1039. doi:10.1007/s11886-023-01924-4.
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
Copyright
Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.